Shares in Novo Nordisk, the Danish maker of Ozempic and Wegovy, tumbled after studies showed the active ingredient in its hit ...
Novo Nordisk said on Tuesday its experimental obesity drug, amycretin, showed statistically significant weight loss of up to ...
Novo has experienced a prolonged sell.off over the last months, declining more than 65% from all-time highs. Why some kind of ...
The pharma giant said amycretin led to weight loss and diabetes reductions in both injection and pill versions.
Novo Nordisk said on Monday that two late-stage trials testing an older oral version of its semaglutide drug failed to meet ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback